520 related articles for article (PubMed ID: 16856618)
1. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
2. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
[TBL] [Abstract][Full Text] [Related]
3. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
[TBL] [Abstract][Full Text] [Related]
4. [Viral breakthrough in HBeAg-negative chronic hepatitis B patients receiving lamivudine therapy].
Chang YJ; Yim JY; Cho NY; Choi CW; Baek SJ; Ahn SH; Choi DW; Kwon YD; Kim SS; Kwon OS; Kim JH; Yeon JE; Song JW; Byun KS; Lee CH
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):397-404. PubMed ID: 12506244
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
6. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
8. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
9. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
10. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
11. No benefit to continue lamivudine therapy after emergence of YMDD mutations.
Liaw YF; Chien RN; Yeh CT
Antivir Ther; 2004 Apr; 9(2):257-62. PubMed ID: 15134188
[TBL] [Abstract][Full Text] [Related]
12. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
[TBL] [Abstract][Full Text] [Related]
13. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
[TBL] [Abstract][Full Text] [Related]
14. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
Chang ML; Chien RN; Yeh CT; Liaw YF
J Hepatol; 2005 Jul; 43(1):72-7. PubMed ID: 15896869
[TBL] [Abstract][Full Text] [Related]
15. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
16. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.
Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Takagi K; Kobayashi M; Ikeda K; Kumada H
J Gastroenterol; 2004 Jan; 39(1):34-40. PubMed ID: 14767732
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
18. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
19. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
20. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
